With the continued disclosure of the Fund's quarterly report in 2024Top1playtoearncryptogamesThe positions of more well-known fund managers surfaced.
A reporter from the Daily Economic News noticed thatTop1playtoearncryptogamesChina Europe Medical and Health, managed by China Europe Fund Glenn, reduced its holdings of Kellein (002821) in the first quarter, while Dong'e E'jiao (000423) was the new top 10. China Europe Medical Innovation reduced its holdings in Hengrui Pharmaceutical (600276), Eye Ophthalmology (300015), Pharmaceutical Biology and other stocks, while Gusheng Hall was among the top 10.
In addition, China Europe New Blue Chip (166002) and China Europe New Trends (166001) managed by Zhou Weiwen of China Europe Fund all reduced their holdings in stocks such as Wen's shares (300498) in the first quarter, and bought stocks such as Zijin Mining.
Still optimistic about the pharmaceutical industry chain.
According to Wind, by the end of the first quarter of 2024, the cumulative size of the three products managed by China Europe Fund Glenn was about 45.9 billion yuan, down from 57.3 billion yuan at the end of 2023.
In terms of positions, CEIBS Medical and Health mainly reduced its holdings in Ayre Ophthalmology, Pian Tsai Kang (600436), Tongrentang (600085) and other stocks in the first quarter, and slightly increased its position in Yao Ming Kant (603259). In addition, Kailiying withdrew from the top ten, and the newcomer was Dong E E Jiao. At the end of 2023, the number of shares held by Dong E E Jiao was only 1182.Top1playtoearncryptogames.350 million shares, which increased to 2150 by the end of the first quarter of 2024.Top1playtoearncryptogames.8,000 shares.
CEIBS Medical Innovation mainly reduced its holdings in Hengrui Pharmaceuticals, Eye Ophthalmology and other stocks in the first quarter. Yao Ming Biological withdrew from the top 10, and Gusheng Hall was the newcomer to the top 10.
Looking ahead to the second quarter, Glenn said: "We are still optimistic about the innovation-driven pharmaceutical industry chain." Overseas, although the pace of interest rate cuts in 2024 is still uncertain, the overall trend of relatively loose liquidity is certain. Domestically, the policy continues to strengthen support for innovation in the field of medicine and biology. As an important part of new quality productivity, pharmaceutical innovation is also the most firm direction of enterprise layout. The number of varieties applying for listing of chemical drugs, biological drugs and traditional Chinese medicine innovative drugs continues to increase in 2023, and it is expected to usher in the peak period of approval and listing of related innovative drugs in 2024. "
Glenn said: "of course, we also see that the development of the domestic innovative drug industry chain is facing certain twists and turns and complexity." The healthy and sustainable development of the industrial chain needs unified coordination from many aspects, such as enterprise financing, product project establishment, R & D promotion, registration application, entering hospital purchase catalogue, compliance sales, health insurance payment and so on. In view of the pain points of each link of the industrial chain, in recent years, the national level has continued to carry out scientific overall planning and precise dredging through policies and measures, and the overall guiding direction of the industrial chain is still a real innovation. mainly reflected in new targets, new mechanisms, new structures, new technologies and drugs with independent intellectual property rights, as well as effective treatments to meet clinical needs. Predictably, the support and guidance at the national policy level is expected to lead to a new round of healthier and sustainable R & D cycle, which also contains opportunities worthy of advance layout. "
Zhou Weiwen reduced his stake in Wen
In addition, Glenn also said: "We also actively follow the progress of the competitive medical industry chain going to sea." With the continuous promotion of the level of internationalization in the field of medical devices, some enterprises have gradually made international breakthroughs in the field of high value chain and occupied overseas market opportunities, mainly focused on innovative equipment, in vitro diagnosis and other fields. Although the internationalization process of some enterprises will be affected by the phased changes in the global geopolitical situation, the long-term core competitiveness of high-quality assets in the domestic innovation industry chain has not changed. "
A reporter from the Daily Business News noted that Zhou Weiwen, a China-Europe fund, currently manages a total of five funds, with a cumulative management scale of about 33.4 billion yuan, of which the mixture of China-EU new blue chips and China-EU new trends has been managed for the longest time, both for more than 12 years.
In the first quarter, CEIBS New Blue Chip mixture mainly reduced its holdings in Guizhou Moutai (600519), Spring Airlines (601021) and other stocks, while increased its positions in Wanhua Chemical (600309) and Zhongji Xuchuang (300308). In addition, a more obvious change is that Wen's shares, Desai Xiwei (002920) and Huatai Securities (601688) all withdrew from the top 10, while the newcomers were Zijin Mining, COSCO Haineng (600026) and General Strategy Medical (600763).
The new trend in China and Europe in the first quarter is mainly to reduce the holdings of Guizhou Moutai (600519), Spring Airlines and other stocks, increased the positions of Wanhua Chemical, Zhongji Xuchuang, Lixun Precision (002475) and other stocks. In addition, Wen's shares withdrew from the top 10, and the newcomer was Zijin Mining.
Generally speaking, Zhou Weiwen's quarterly report mainly adds the computing power related to the AI (artificial intelligence) industry chain, downstream application companies, and upstream resource products that benefit from the physical cycle and liquidity cycle.
In addition, Zhou Weiwen said in the first quarterly report: "the high dividend sector performs better because in the context of low interest rates and high-quality growth, the dividend yield has become an important consideration for the underlying asset allocation of some long-term institutions." AI industry performed well because of the newly released model, Vincent video application made a breakthrough, the market expected the progress of AI industry development ahead of schedule, AI video and AI application-related targets were sought after by the market. The better performance of non-ferrous metals such as gold and copper is the combined effect of the expectation of interest rate cuts in the United States, limited supply and other factors. "